Revisiting mTOR inhibitors as anticancer agents

Qiu Xu Teng, Yunali V. Ashar, Pranav Gupta, Eddie Gadee, Ying Fang Fan, Sandra E. Reznik, John N.D. Wurpel, Zhe Sheng Chen

Research output: Contribution to journalReview article

3 Scopus citations

Abstract

The mammalian target of rapamycin (mTOR) is a highly conserved serine/threonine kinase that regulates a variety of cellular processes, influencing diverse pathological conditions including a variety of cancers. Accordingly, therapies that target mTOR as anticancer agents benefit patients in various clinical settings. It is therefore important to fully investigate mTOR signaling at a molecular level and corresponding mTOR inhibitors to identify additional clinical opportunities of targeting mTOR in cancers. In this review, we introduce the function and regulation of the mTOR signaling pathway and organize and summarize the different roles of mTOR in cancers and a variety of mTOR inhibitors that can be used as anticancer agents. This article aims to enlighten and guide the development of mTOR-targeted anticancer agents in the future.

Original languageEnglish (US)
Pages (from-to)2086-2095
Number of pages10
JournalDrug Discovery Today
Volume24
Issue number10
DOIs
StatePublished - Oct 2019

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Fingerprint Dive into the research topics of 'Revisiting mTOR inhibitors as anticancer agents'. Together they form a unique fingerprint.

  • Cite this

    Teng, Q. X., Ashar, Y. V., Gupta, P., Gadee, E., Fan, Y. F., Reznik, S. E., Wurpel, J. N. D., & Chen, Z. S. (2019). Revisiting mTOR inhibitors as anticancer agents. Drug Discovery Today, 24(10), 2086-2095. https://doi.org/10.1016/j.drudis.2019.05.030